This product is not assigned an expiration date or recommended retest date. Products with no expiration date or recommended retest date should be routinely inspected by customers to ensure they perform as expected. These products are also subject to a one-year warranty from the date of shipment. For more information, you may access the Product Dating Information document under ADDITIONAL USEFUL DOCUMENTS ABOUT OUR PRODUCTS at the bottom of the Quality Services page with this link: https://www.sigmaaldrich.com/life-science/quality-and-regulatory-management/quality-services.
Wszystkie zdjęcia(3)
Kluczowe dokumenty
S4317
SB 431542 hydrate
≥98% (HPLC), powder, inhibits activation of SMAD proteins
Synonim(y):
4-(5-Benzol[1,3]dioxol-5-yl-4-pyrldin-2-yl-1H-imidazol-2-yl)-benzamide hydrate, 4-[4-(1,3-Benzodioxol-5-yl)-5-(2-pyridinyl)-1H-imidazol-2-yl]-benzamide hydrate, 4-[4-(3,4-Methylenedioxyphenyl)-5-(2-pyridyl)-1H-imidazol-2-yl]-benzamide hydrate
Zaloguj sięWyświetlanie cen organizacyjnych i kontraktowych
Wybierz wielkość
5 MG
1240,00 zł
1240,00 zł
Skontaktuj się z Obsługą Klienta, aby uzyskać informacje na temat dostępności
Poproś o zamówienie zbiorcze
Wybierz wielkość
Zmień widok
5 MG
1240,00 zł
About This Item
Wzór empiryczny (zapis Hilla):
C22H16N4O3 · xH2O
Numer CAS:
Masa cząsteczkowa:
384.39 (anhydrous basis)
Numer MDL:
Kod UNSPSC:
51111800
Identyfikator substancji w PubChem:
NACRES:
NA.77
1240,00 zł
Skontaktuj się z Obsługą Klienta, aby uzyskać informacje na temat dostępności
Poproś o zamówienie zbiorcze
Polecane produkty
Nazwa produktu
SB 431542 hydrate, ≥98% (HPLC), powder
Próba
≥98% (HPLC)
Formularz
powder
rozpuszczalność
DMSO: soluble 10 mg/mL
H2O: insoluble
inicjator
GlaxoSmithKline
temp. przechowywania
−20°C
ciąg SMILES
O.NC(=O)c1ccc(cc1)-c2nc(-c3ccc4OCOc4c3)c([nH]2)-c5ccccn5
InChI
1S/C22H16N4O3.H2O/c23-21(27)13-4-6-14(7-5-13)22-25-19(20(26-22)16-3-1-2-10-24-16)15-8-9-17-18(11-15)29-12-28-17;/h1-11H,12H2,(H2,23,27)(H,25,26);1H2
Klucz InChI
WQUIJVKNPYBZOF-UHFFFAOYSA-N
Zastosowanie
Działania biochem./fizjol.
Potent and selective inhibitor of transforming growth factor-β superfamily type I activin receptor-like kinase (ALK) receptors.
Cechy i korzyści
This compound was developed by GlaxoSmithKline. To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here.
Informacje prawne
Sold for research purposes under agreement from GlaxoSmithKline
Ta strona może zawierać tekst przetłumaczony maszynowo.
Kod klasy składowania
11 - Combustible Solids
Klasa zagrożenia wodnego (WGK)
WGK 3
Temperatura zapłonu (°F)
Not applicable
Temperatura zapłonu (°C)
Not applicable
Środki ochrony indywidualnej
Eyeshields, Gloves, type N95 (US)
Wybierz jedną z najnowszych wersji:
Certyfikaty analizy (CoA)
Lot/Batch Number
Nie widzisz odpowiedniej wersji?
Jeśli potrzebujesz konkretnej wersji, możesz wyszukać konkretny certyfikat według numeru partii lub serii.
Masz już ten produkt?
Dokumenty związane z niedawno zakupionymi produktami zostały zamieszczone w Bibliotece dokumentów.
Klienci oglądali również te produkty
N J Laping et al.
Molecular pharmacology, 62(1), 58-64 (2002-06-18)
Transforming growth factor beta1 (TGF-beta1) is a potent fibrotic factor responsible for the synthesis of extracellular matrix. TGF-beta1 acts through the TGF-beta type I and type II receptors to activate intracellular mediators, such as Smad proteins, the p38 mitogen-activated protein
A Smad3 and TTF-1/NKX2-1 complex regulates Smad4-independent gene expression.
Isogaya K, Koinuma D, Tsutsumi S, et al.
Cell Research, 24(8), 994-1008 (2014)
Mark D Hjelmeland et al.
Molecular cancer therapeutics, 3(6), 737-745 (2004-06-24)
Transforming growth factor-beta (TGF-beta) is a multifunctional cytokine that promotes malignant glioma invasion, angiogenesis, and immunosuppression. Antisense oligonucleotide suppression of TGF-beta(2) ligand expression has shown promise in preclinical and clinical studies but at least two ligands mediate the effects of
Douglas S Micalizzi et al.
The Journal of clinical investigation, 119(9), 2678-2690 (2009-09-04)
Inappropriate activation of developmental pathways is a well-recognized tumor-promoting mechanism. Here we show that overexpression of the homeoprotein Six1, normally a developmentally restricted transcriptional regulator, increases TGF-beta signaling in human breast cancer cells and induces an epithelial-mesenchymal transition (EMT) that
Ernst J A Steller et al.
Neoplasia (New York, N.Y.), 15(2), 204-217 (2013-02-27)
In epithelial tumors, the platelet-derived growth factor receptor B (PDGFRB) is mainly expressed by stromal cells of mesenchymal origin. Tumor cells may also acquire PDGFRB expression following epithelial-to-mesenchymal transition (EMT), which occurs during metastasis formation. Little is known about PDGFRB
Protokoły
Step-by-step culture protocols for neural stem cell culture including NSC isolation, expansion, differentiation and characterization.
-
If not reconstituted for how long can I store the vial?
1 answer-
Helpful?
-
-
How long can I store the reconstituted compound in the freezer -20 degrees? i have one that was aliquoted 4 years ago. Is it still ok to use it ?
1 answer-
It is recommended, following reconstitution, to aliquot and freeze -20°C. The stock solutions are stable for up to 6 months at -20°C. The quality of solutions stored frozen for extended periods has not been evaluated. The end user would have to determine suitability. Any color change, cloudiness, or particulate matter present upon thawing would be a visual indicator of degradation.
Helpful?
-
Active Filters
Nasz zespół naukowców ma doświadczenie we wszystkich obszarach badań, w tym w naukach przyrodniczych, materiałoznawstwie, syntezie chemicznej, chromatografii, analityce i wielu innych dziedzinach.
Skontaktuj się z zespołem ds. pomocy technicznej
